How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,243 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients

Posted : April 5, 2018 See Sponsor: Pooja Budhiraja, MD Information provided by (Responsible Party): Pooja Budhiraja, MD, University of Kansas Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication. Condition or disease Intervention/treatment Phase Diarrhea Drug: Entocort Drug: Placebos Phase 2 (...) Measures Go to Primary Outcome Measures : Complete remission of diarrhea [ Time Frame: Week 8 ] Measured using symptom diary. Complete remission (CR) is defined as a mean of <3 stools/day and a mean of <1 watery stool per day without use of anti-diarrheal drugs. Secondary Outcome Measures : Change in Gastrointestinal Symptom Rating Scale (GSRS) [ Time Frame: Change from Baseline to Week 8 ] GSRS is a 15-item instrument designed to assess the symptoms associated with common GI disorders. The GSRS

2016 Clinical Trials

42. Bacillus Particles Prevent Children Antibiotics Associated Diarrhea

Prevent Children Antibiotics Associated Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02993419 Recruitment Status : Unknown Verified December 2016 by Jiangsu Famous Medical Technology Co., Ltd.. Recruitment status was: Not yet recruiting First Posted : December 15, 2016 Last Update Posted (...) years old,by observing the given antibiotics at the same time with the whole bowel raw or placebo, prevent the happening of the antibiotic associated diarrhea, evaluate the whole bowel prevention clinical efficacy and safety of AAD. Outcome measures MAIN OUTCOME MEASURES: The incidence of diarrhea (stool frequency and character daily rates), the duration of diarrhea, the degree of diarrhea occur. Secondary outcomes: intestinal flora and relevant metabolites, micro-environmental changes. Study Design

2016 Clinical Trials

43. Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea

with study drug and placebo during the period of prophylaxis and through the last clinic visit. [ Time Frame: 7 weeks ] To assess the effectiveness of CBS 2004 by evaluating the development of traveler's diarrhea (TD) with CBS-2004 versus placebo based on time to first unformed stool associated with a TD episode [ Time Frame: 7 weeks ] Secondary Outcome Measures : Assess the number of work days lost due to diarrhea [ Time Frame: 7 weeks ] Assess percentages of subjects requiring treatment for diarrhea (...) Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Trial of CBS-2004

2016 Clinical Trials

44. Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders

drink 2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28) Outcome Measures Go to Primary Outcome Measures : Occurrence of AAD [ Time Frame: From Day 0 to Day 28 ] Secondary Outcome Measures : Duration of AAD [ Time Frame: From Day 0 to Day 28 ] Time to event of AAD [ Time Frame: From Day 0 to Day 28 ] Occurrence of Clostridium difficile Associated Diarrhea [ Time Frame: From Day 0 to Day 28 ] Time to event of Clostridium (...) Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2016 Clinical Trials

45. Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2016 Clinical Trials

46. Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea

of China Academy of Chinese Medical Sciences: IBS-D; Chang'an I Recipe; Placebo Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Diarrhea Irritable Bowel Syndrome Disease Pathologic Processes Signs and Symptoms, Digestive Signs and Symptoms Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases (...) Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2016 Clinical Trials

47. Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD)

the intervention period of 6 weeks after starting antibiotic treatment; diarrhea is defined according WHO Secondary Outcome Measures : Cumulated duration of antibiotic-associated diarrhea (AAD) [ Time Frame: 6 weeks ] Number of days with diarrhea within the intervention period Gastrointestinal Symptom Rating Scale [ Time Frame: 6 weeks ] Standardized questionnaire according Dimenäs et al. Cumulative sverity of antibiotic-associated diarrhea (AAD) [ Time Frame: 6 weeks ] Sum of the values (obtained (...) Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD) Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2016 Clinical Trials

48. Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency and frequency data and symptom data will be collected. Patients will then be randomized 60:40 to RHB-102 12 mg (BEKINDA) or placebo. Patients will continue on treatment for 8 weeks. Each medication will be given once daily. Condition or disease Intervention/treatment Phase Irritable Bowel Syndrome With Diarrhea Drug: BEKINDA Drug: Placebo Phase 2 Detailed Description (...) Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2016 Clinical Trials

49. To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

as change from baseline in stool types per Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify feces on a scale from 1 to 7 according to increasing wateriness. Secondary Outcome Measures : Area under the plasma concentration-time profile (AUCtau) of LJN452 [ Time Frame: Day 1 (upto 8 hours), Day 2 (pre-dose) and Day 12 (upto 8 hours) in each treatment period ] Maximum plasma concentration (Cmax) of LJN452. [ Time Frame: Day 1 (upto 8 hours), Day 2 (pre-dose) and Day 12 (...) To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea. To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2016 Clinical Trials

50. Acute Diarrhea

, Diarrhea , Acute Infectious Diarrhea , Infectious Diarrhea , Bacterial Diarrhea From Related Chapters II. Definition Inflammation of the gastrointestinal tract ( e and ) Typical presentation is followed by Diarrhea Most typically secondary to Can also be caused by with ingestion of preformed toxin Diarrhea Frequent liquid stools Adults: >200 g/day of stool (at least 3 s daily) Children: >20 g/kg/day of stool Timing Acute Diarrhea: Duration <2 weeks : Duration >4 weeks III. Epidemiology Foodbourne (...) es (30-40% of episodes) (90% of non- l diarhea) and s (20-30% of episodes) Inflammatory Diarrhea from and s (most common ) Shiga-toxin producing (e.g. :H7, ) Causes 30% of infectious bloody Diarrhea Non-inflammatory Diarrhea from and s Bacillus cereus VII. Risk Factors See for systemic medical condition causes of Diarrhea See Recent travel to endemic area See Travel to a developing area is associated with a 25% chance of developing Diarrhea Those with Diarrhea in a developing area have an 80

2018 FP Notebook

51. Antibiotic Associated Diarrhea

Diarrhea Antibiotic Associated Diarrhea Aka: Antibiotic Associated Diarrhea , Diarrhea Secondary to Antibiotic Use , Antibiotic-Associated Diarrhea From Related Chapters II. Precautions Antibiotics in the emergency department frequently cause IV antibiotics: 26% of cases Oral antibiotics: 12% of cases , and antibiotic combinations were highest risk for Reconsider whether antibiotics are indicated and if so, if IV route is needed Oral bioavailability of most antibiotics is excellent Single dose IV (...) antibiotics prior to home oral antibiotics is rarely indicated References Arora and Menchine in Herbert (2015) EM:Rap 15(1): 11 III. Causes: Bacterial Overgrowth Syndromes secondary to antibiotics oxytoca Responds to stopping antibiotics (and possibly to stopping s) IV. Prevention: Probiotics Efficacy (NNT): 13 Treating 13 patients prevents one case of Antibiotic Associated Diarrhea Live-culture yogurt reduces due to antibiotics Lactobacillus acidophilus Lactobacillus bulgaricus thermophilus Other

2018 FP Notebook

52. Diarrhea in HIV

) These images are a random sampling from a Bing search on the term "Diarrhea in HIV." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Diarrhea About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content (...) Diarrhea in HIV Diarrhea in HIV Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea in HIV Diarrhea in HIV Aka: Diarrhea in HIV

2018 FP Notebook

53. Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea

to Primary Outcome Measures : Efficacy: Cure of diarrhea without recurrence in intention to treat population [ Time Frame: 56 days ] Cure is defined as less than 3 bowel motions per day for 2 consecutive days during the 10 day treatment period. Recurrence is defined as 3 or more bowel motions within one day during the follow-up period. Adverse Events [ Time Frame: 56 days ] Number of participants with treatment-related adverse events as defined by the Medical Dictionary for Regulatory Activities (...) . Secondary Outcome Measures : Efficacy: Cure of diarrhea without recurrence in a per protocol population [ Time Frame: 56 days ] Cure is defined as less than 3 bowel motions per day for 2 consecutive days during the 10 day treatment period. Recurrence is defined as 3 or more bowel motions within one day during the follow-up period. Efficacy: cure of diarrhea in intention to treat and per protocol populations [ Time Frame: 10 days ] Cure is defined as less than 3 bowel motions per day for 2 consecutive

2016 Clinical Trials

54. Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

Phase Diarrhea Metastatic Renal Cell Cancer Stage IV Renal Cell Cancer Other: Laboratory Biomarker Analysis Dietary Supplement: Micronutrient-Fortified Probiotic Yogurt Drug: VEGF‐TKI Not Applicable Detailed Description: PRIMARY OBJECTIVES: I. To determine if adding Activia yogurt (containing Bifidobacterium lactis DN-173 010) to the diet of patients with metastatic renal cell carcinoma (mRCC) increases the level of Bifidobacterium spp in stool. SECONDARY OBJECTIVES: I. To determine if Activia (...) between patients with or without Activia added to the diet. Secondary Outcome Measures : Incidence of diarrhea as graded by the Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 13 weeks ] The rate of all grade diarrhea will be compared in the patients who receive the dietary supplement and those who do not. The rate of grade 3/4 diarrhea will also be compared between the two groups. A Fisher's exact test with a 0.050 one-sided significance level will be used. Levels

2016 Clinical Trials

55. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy MASCC=ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy Rajesh V. Lalla, DDS, PhD 1 ; Joanne Bowen, PhD 2 ; Andrei Barasch, DMD, MDSc 3 ; Linda Elting, PhD 4 ; Joel Epstein, DMD, MSD 5 ; Dorothy M. Keefe, MD 2 ; Deborah B. McGuire, PhD, RN 6 ; Cesar Migliorati, DDS, MS, PhD 7 ; Ourania Nicolatou-Galitis, DDS, MSc, DrDent 8 ; Douglas E. Peterson, DMD (...) , University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030-1605; Fax: (860)679-4760; Lalla@uchc.edu 1 University of Connecticut, Farmington, Connecticut; 2 University of Adelaide, Adelaide, South Australia, Australia; 3 Winthrop University Hospital, Mineola, New York; 4 The University of Texas MD Anderson Cancer Center, Houston, Texas; 5 City of Hope Medical Center, Duarte, California; 6 Virginia Commonwealth University, Richmond, Virginia; 7 University of Tennessee Health Science

2014 International Society for Oral Oncology

56. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

Summary 4-30 Evidence Base 30 Post-hoc Question: By inductive evaluation of all evidence-based recommendations, what are the core recommendations for medical care of patients with obesity? 30 Q1. Do the 3 phases of chronic disease prevention and treatment (i.e., primary, secondary, and tertiary) apply to the disease of obesity? 31 Q2. How should the degree of adiposity be measured in the clinical setting? 33 Q2.1. What is the best way to optimally screen or aggressively case-find for overweight (...) : By inductive evaluation of all evi- dence-based recommendations, what are the core recom- mendations for medical care of patients with obesity? Obesity and 3 Phases of Chronic Disease Prevention and Treatment • Q1. Do the 3 phases of chronic disease prevention and treatment (i.e., primary, secondary, and tertiary) apply to the disease of obesity? The Anthropometric Component of the Diagnosis of Obesity • Q2. How should the degree of adiposity be measured in the clinical setting? • Q2.1. What is the best

2016 American Association of Clinical Endocrinologists

57. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature (PubMed)

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature BACKGROUND DRESS is a rare, life threatening syndrome that occurs following exposure to certain medications, most commonly antibiotics and antiepileptics. While sulfonamide antibiotics are frequently implicated as causative agents for DRESS syndrome, furosemide, a nonantibiotic sulfonamide, has not been routinely reported as the causative agent despite its (...) . CONCLUSIONS We report a case of severe DRESS syndrome secondary to furosemide, only the second case report in medical literature implicating furosemide. Given its widespread use, the potentially life-threatening nature of DRESS syndrome and the commonly delayed time course in establishing the diagnosis, it is important to remember that, albeit rare, furosemide can be a cause of DRESS syndrome.

Full Text available with Trip Pro

2018 The American journal of case reports

58. Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea

of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: PTM202 PTM202 is a medical nutrition product Other: PTM202 Placebo Comparator: Placebo The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor Other: Placebo Outcome Measures Go to Primary Outcome Measures : diarrhea duration [ Time Frame: 7 days ] Secondary Outcome Measures : food intake [ Time Frame: 7 days ] stool frequency [ Time Frame: 7 (...) Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study With Medical

2013 Clinical Trials

59. Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

allergy to Lanthanum Carbonate hypophosphatemia (defined as serum phosphorus < 0.81 mmol/L) severe known liver insufficiency of biliary obstruction rectocolitis ulcerohaemorraghica, Crohn's disease, bowel obstruction, stomach/duodenal ulceration glucose/galactose malabsorption severe diarrhea or other gastrointestinal disorder, which might interfere with the ability to absorb oral medication pregnancy or breast-feeding female participant of childbearing potential unwilling to take efficient (...) Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

60. Chronicles of a Second Year Medical Student

Chronicles of a Second Year Medical Student Chronicles of a Second Year Medical Student – Clinical Correlations Search Chronicles of a Second Year Medical Student August 6, 2015 5 min read By Matthew Siow Peer Reviewed Day 1 of the medicine rotation: complete. I was on long call today, which meant three things. One, the hours during which I had to pretend I knew something were longer. Two, I saw a lot of things I had never seen before, from more common things like COPD exacerbations and acute (...) of cake. I’ll do a couple questions tonight just to get my feet wet. You know what they say: a journey of 1,397 questions begins with a single step. Question 1 A 65-year-old male comes to your office to establish care. He tells you he has spent the last 40 years working as a shark tank tester in Botswana and once came within 100 feet of touching a shark. He believes this close encounter has led him to develop an allergy to shark fin soup. He takes no medications but admits taking “some kind

2015 Clinical Correlations

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>